Title : Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.

Pub. Date : 2011 Oct

PMID : 21903741






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This pilot study examines the correlation of PET using (11)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline epidermal growth factor receptor Homo sapiens
2 This pilot study examines the correlation of PET using (11)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline epidermal growth factor receptor Homo sapiens
3 This pilot study examines the correlation of PET using (11)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline epidermal growth factor receptor Homo sapiens